

ImmuteP Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

SYDNEY, AUSTRALIA – July 28, 2025 – [ImmuteP Limited](#) (ASX: IMM; NASDAQ: IMMP) (“ImmuteP” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces three abstracts for clinical trials evaluating its first-in-class MHC Class II agonist, eftilagimod alfa (efti), have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025 taking place 17-21 October in Berlin, Germany.

A Proffered Paper oral presentation will detail results from EFTISARC-NEO, a Phase II investigator-initiated trial in resectable soft tissue sarcoma, and data from the INSIGHT-003 Phase I investigator-initiated trial in first-line non-small cell lung cancer (1L NSCLC) has been accepted for poster presentation. Additionally, an abstract on the Company’s pivotal TACTI-004 Phase III in 1L NSCLC has been accepted for a Trials in Progress ePoster. Details of the presentations are as follows:

Title: EFTISARC-NEO: A phase II study of neoadjuvant eftilagimod alfa, pembrolizumab and radiotherapy in patients with resectable soft tissue sarcoma
Presenter: Katarzyna Kozak, M.D., Ph.D., Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Session Category: Proffered Paper
Session Title: Sarcoma
Presentation #: 2686O
Date and Time: Sunday, 19 October 2025 at 16:30 – 18:00 PM CET

Title: Eftilagimod alfa (soluble LAG-3 protein) combined with 1st line chemo-immunotherapy in metastatic non-squamous non-small cell lung cancer (NSCLC) – Updates from INSIGHT-003 (IKF614)
Presenter: Dr. med. Akin Atmaca, Department of Hematology and Oncology, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany
Session Category: Poster
Session Title: NSCLC, metastatic
Presentation #: 1857P
Date and Time: Saturday, 18 October 2025 at 12:00 – 12:45 PM CET

Title: TACTI-004, a double-blinded, randomised phase 3 trial of eftilagimod alfa plus pembrolizumab (P) + chemotherapy (C) vs placebo + P + C in 1st line advanced/metastatic NSCLC
Presenter: Prof. Dr. med. Hans-Georg Kopp, Robert Bosch Hospital, Stuttgart, Germany
Session Category: ePoster
Session Title: NSCLC, metastatic
Presentation #: 2086eTiP

Proffered Papers at ESMO are oral presentations of original data of superior quality, followed by expert discussion and perspectives.

Abstracts will be made available on the ESMO website on 13 October 2025 at 00.05 CET. The posters will be available on the Posters & Publications section of Immutep's website after their presentations.

About Immutep

Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Australian Investors/Media:

Eleanor Pearson, Sodali & Co.

+61 2 9066 4071; eleanor.pearson@sodali.com

U.S. Media:

Chris Basta, VP, Investor Relations and Corporate Communications

+1 (631) 318 4000; chris.basta@immutep.com

This announcement was authorised for release by the CEO of Immutep Limited.